Video Series

A panel of multiple myeloma experts discuss costs associated with relapsed/refractory disease.

Treatment considerations for relapsing multiple myeloma is discussed by key opinion leaders.

Brian Keegan, MD, PhD, and Michael Cameron, MD, FAAD, describe treatment options for patients with atopic dermatitis.

Dr Casey Butrus drives a discussion highlighting typical patient presentations of AD.

In their final thoughts, the panelists explore the future of GA treatment strategies.

Dr Khanani discusses how to monitor patients with geographic atrophy for adverse events.

Key opinion leaders discuss clinical and cost considerations for treating patients diagnosed with geographic atrophy.

A medical expert discusses preauthorization requests and requirements for cardiovascular disease treatment, commenting on an abstract presented at the ACC 2023 Annual Scientific Session and Expo and World Congress of Cardiology.

Expert panelists discuss considerations for RRMM treatment strategies.

Key opinion leaders navigate diagnostic challenges associated with atopic dermatitis.

Casey Butrus, PharmD, leads a panel of experts in a discussion surrounding atopic dermatitis.

Dr Lopes provides insights into payer considerations when navigating geographic atrophy treatment pathways.

Drs Lally and Khanani expand on key takeaways from the GATHER1 and GATHER2 studies.

Dr Michos examines a controlled trial focusing on co-payment elimination and its effects on cardiovascular outcomes for low-income adults.

In his closing thoughts, Dr Marshall shares final takeaways from the 2023 ASCO GI Cancers Symposium.

The GATHER1 and GATHER2 studies are highlighted.

Medical experts recap the DERBY and OAKS studies.

Hypercholesterolemia impact on cardiovascular outcomes is explored by a key opinion leader.

The SPOTLIGHT study results presented at the 2023 ASCO GI Cancers Symposium are explored by Dr Marshall.

Dr Michos offers strategies to successfully reduce LDL levels in patients with cardiovascular disease.

GA treatment options in various steps in FDA approval process are discussed by a panel of medical experts.

Maria Lopes, MD, MS, highlights the utilization of health care resources to optimize GA treatment impact.

Dr Marshall shares insights directed at the use of real-world evidence [RWE] and its impact on unmet needs in colorectal cancer [CRC] treatment.

Erin Michos, MD, MHS, opens a discussion surrounding the utilization of bempedoic acid for patients with intolerance to statin-based therapies.

Dr Haumschild leads a discussion surrounding comorbidities associated with geographic atrophy.

David Lally, MD, highlights risk factors associated with geographic atrophy.

In their closing thoughts, the expert panelists discuss the future of the disease state and treatment options, and how they expect provider, patient, and payer value perception to change in the future.

The panelists discuss how payers can best engage with the retinal disease community on a provider and patient level.